The unresectable melanoma market is anticipated to grow at a CAGR of 4.20% during the forecast period of 2025-2034, driven by growing demand for personalized therapies across 8 major markets.
Base Year
Historical Year
Forecast Year
The shift toward personalized medicine is fueling the unresectable melanoma market. Increased investments in combination therapies are driving market expansion, fulfilling the need for efficient treatment alternatives.
In February 2024, Amtagvi became the first cellular therapy for unresectable melanoma approved by the FDA. Such approvals signify the increasing adoption of creative therapies, motivating more investigation and establishing fresh benchmarks in cancer treatment.
The United States is expected to dominate the market due to well-established healthcare infrastructure, better and advanced medical facilities, and significant spending on healthcare.
Unresectable melanoma is a type of cancer that can't be surgically removed and hence needs specialized treatments that usually involve immunotherapy or targeted therapies. Advancements in immunotherapy, personalized medicine, and increased funding for clinical trials are some of the key factors promoting innovation. The latest trends include a focus on the advancement of cellular treatments, early detection techniques, and improved screening methods. These developments drive market expansion by fulfilling the strong need for efficient treatment choices, promoting investments, and broadening therapeutic options in the market.
Advancements in Immunotherapy Drives Market Growth
Immunotherapy treatments, including PD-1 & CTLA-4 inhibitors, as they deliver better patient outcomes for unresectable melanoma and enable the immune system to attack the tumor cells. Such advancements in the field trigger the growth of the market by exponentially growing options for treatment, enabling healthcare providers to adopt the therapy extensively.
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
Market Breakup by Melanoma Stage:
Market Breakup by Route of Administration:
Market Breakup by Distribution Channel:
Market Breakup by Region:
Market Segmentation Based on Distribution Channel Holds a Significant Market Share
The market is divided into hospitals pharmacies, online pharmacies, retail pharmacies, and others based on the distribution channel. Among these, hospitals pharmacies are expected to dominate the market because they serve as key facilities for medical care, providing access to various specialists. This dominance boosts market share by concentrating patient access and driving demand for advanced diagnostic equipment, strengthening overall market growth.
Based on region, the market report covers the United States, EU-4, and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. Among these, the United States is expected to lead the market due to the sophisticated healthcare infrastructure and pharmaceutical companies playing a role in drug development. The market is expanding as there is an increased focus on early detection and personalized treatment options. In addition, government support encourages market growth by leading clinical trials and introducing innovative treatments like targeted therapies.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
AstraZeneca, based in the United Kingdom, is a large biopharmaceutical multinational company that mainly focuses on research. The corporation has a big footprint in the unresectable melanoma market due to Imfinzi (durvalumab), an immunological treatment inhibiting the PD-L1 molecule in the body and reenables the immune system to detect and confront cancer cells.
Headquartered in New York and a leading player in immuno-oncology research, Bristol-Myers Squibb Company develops many types of immunotherapy drugs, including Opdivo (nivolumab). Opdivo is a PD-1 inhibitor designed to stimulate immunity by enabling the immune system to detect and eliminate tumor cells.
The Novartis AG is an integrated global healthcare leader in the pharmaceutical and generics sectors, based in Switzerland. It offers combination therapies like dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with unresectable melanoma possessing specific genetic mutations.
Pfizer Inc., a global leader based in New York, provides a range of therapies for unresectable melanoma. Their key portfolio includes products like Braftovi (encorafenib) in conjunction with Mekinist for treating melanoma, specifically for those with BRAF V600E or V600K mutation.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Amgen Inc., Bayer AG, F. Hoffman-La Roche Ltd., Genentech, Inc., Merck & Co. Inc., GlaxoSmithKline Plc., Agilent Technologies, and Sanofi S.A.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Melanoma Stage |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share